Genetic diversity and new therapeutic concepts

Journal of Human Genetics

Volumn 50, Issue 7, 2005, Pages 321-328

  Shastry, Barkur S ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

Gene; Medicine; Pharmacogenetics; Pharmacogenomics; Polymorphism

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ABACAVIR; ABC TRANSPORTER; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARRIER PROTEIN; CIMETIDINE; CIPROFLOXACIN; CLOZAPINE; CODEINE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DRUG METABOLIZING ENZYME; EFAVIRENZ; ENZYME INHIBITOR; FLUOROURACIL; GEMCITABINE; IRINOTECAN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; PHENYTOIN; PRAVASTATIN; PREDNISONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; UNINDEXED DRUG; WARFARIN;

ACCURACY; AUTOIMMUNE DISEASE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; DNA MICROARRAY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INTOXICATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; ENZYME DEFICIENCY; GENE DELETION; GENE INSERTION; GENE TARGETING; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME PROJECT; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MEDICAL ETHICS; MEDICOLEGAL ASPECT; MOLECULAR GENETICS; MORALITY; MORTALITY; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PRESCRIPTION; RISK BENEFIT ANALYSIS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

GENOME, HUMAN; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; VARIATION (GENETICS);

EID: 23944484940     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-005-0264-6     Document Type: Short Survey

References (95)

1. Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD, Maruyama Y, Kobayashi M, Wood NW, Spurr NK, Burns DK, Roses AD, Saunders AM, Goldstein DB (2005) A single nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 37:84-89
2. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719
3. Akio I (2003) Neuropeptide gene polymorphisms and human behavioral disorders. Nat Rev Drug Discov 2:986-998
4. Ament PW, Bertolino JG, lliszewski JL (2000) Clinically significant drug interactions. Am Fam Physician 61:1745-1754
5. Arnett DK, Claas SA (2004) Pharmacogenetics of antihypertensive treatment. Drug Dev Res 62:191-199
6. Balis FM, Adamson PC (1999) Application of pharmacogenetics to optimization of mercaptopurine dosing. J Natl Cancer Inst 91:1983-1984
7. Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H (2004) Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 5:676-680
8. Caraco Y (2004) Genes and the response to drugs. N Engl J Med 351:2867-2869
9. Cha PC, Yamada R, Sekine A, Nakamura Y, Koh CL (2004) Inference from the relationships between linkage disequilibrium and allele frequency distribution of 240 candidate SNPs in 109 drug-related genes in four Asian populations. J Hum Genet 49:558-572
10. Charasson V, Bellott R, Meynard D, Lougy M, Gorry P, Robert J (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76:528-535
11. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821-2827
12. Chen GL, Zhu B, Nie WP, Xu ZH, Tan ZR, Zhou G, Liu J, Wang W, Zhou HH (2004) Single nucleotide polymorphisms and haplotypes of histamine- N-methyltransferase in patients with gastric ulcer. Inflamm Res 53:484-488
13. Daly AK (2004) Pharmacogenetics of the cytochrome P450. Curr Top Med Chem 4:1733-1744
14. De Jong FA, Marsh S, Mathijssen RHJ, King C, Verweij J, Sparreboom A, McLeod HL (2004) ABCG2 pharmacogenetics: ethnic difference in allelic frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889-5894
15. Donnelly JG (2004) Pharmacogenetics in cancer chemotherapy-balancing toxicity and response. Ther Drug Monitor 26:231-235
16. Dormann H, Neubert A, Criegee-Rieck M, Radespiel-Troger M, Azaz-Livshits T, Levy M, Brune K, Hahn EG (2004) Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med 255:653-663
17. Doyle AES, Goodman JE, Silber PM, Yager JD (2004) Catechol-O- methyltransferase low activity genotype (COMTLL) is associated with low levels of COMT protein in human hepatocyte. Cancer Lett 214:189-195
18. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J (1999) Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22:168-170
19. Evans WE, Johnson JA (2001) Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9-39
20. Evans WE, McLeod HL (2003) Pharmacogenomics - drug disposition, drug targets and side effects. N Engl J Med 348:538-549
21. Evans WE, Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468
22. Fabre MA, Jones DC, Bunce M, Morris PJ, Friend PJ, Welsh KI, Marshall SC (2004) The impact of thiopurine 5-methyltransferase polymorphism on a azathioprine dose 1 year after renal transplantation. Transpl Int 17:531-539
23. Ferraccioli G, De Santis M, Tolusso B (2004) Pharmacogenetics/ pharmacogenomics and anti-rheumatic drugs in rheumatology. Pharmacogenomics 5:1107-1116
24. Fierz W (2004) Challenges of personalized health care: to what extent is medicine already individualized and what are the future trends? Med Sci Monitor 10:RA111-RA123
25. Formea CM, Myers-Huentelman H, Wu RL, Crabtree J, Fujita S, Hermming A, Reed A, Howard R, Karlix JL (2004) Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am J Transpl 4:1810-1817
26. Freimuth RR, Ameyaw M, Pritchard SC, Kwok P-Y, McLeod HL (2004) High-throughput genotyping methods for pharmacogenomic studies. Curr Pharmacogenomics 2:21-33
27. Fukunaga AK, Marsh S, Murray DJ, Hurley TD, McLeod HL (2004) Identification and analysis of single nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4:307-314
28. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW (2003) Adverse drug events in ambulatory care. N Engl J Med 348:1556-1564
29. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827-2831
30. Goldstein D B, Tate SK, Sisodiya SM (2003) Pharmacogenetics goes genomic. Nat Rev Genet 4:937-947
31. Gut I (2001) Automation in genotyping of single nucleotide polymorphisms. Hum Mutat 17:475-492
32. Haas DW (2004b) Pharmacogenomics of antiretroviral therapy. Drug Dev Res 62:213-220
33. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP (2004a) Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trails group study. AIDS 18:2391-2400
34. Hakonarsson H, Stefansson K (2004) Role of pharmacogenomics in drug development. Drug Dev Res 62:86-96
35. Hall ST, Abbott N, Schmith G, Brazell C (2004) Pharmacogenetics in drug development: regulatory and clinical considerations. Drug Dev Res 62:102-111
36. Haller-Gloor F, Eap CB, Turgeon J, Baumann P (2004) High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. Int J Psychiatry Clin Pract 8:191-195
37. Hildebrandt AG (2004) Pharmacology, drug efficacy and the individual. Drug Metab Rev 36:845-852
38. Huang G, Xing HX, Hao K, Peng SJ, Wu D, Guang WW, Huang AQ, Hong XM, Wang YP, Feng Y, Zhang Y, Li JP, Chen CZ, Wang GY, Huo Y, Chen DF, Hou YT, Wang XB, Xu X, Niu TH, Xu XP (2004) Beta (2) adrenergic receptor gene Arg16Gly polymorphism is associated with therapeutic efficacy of benazepril on essential hypertension in Chinese. Clin Exp Hypertens 26:581-592
39. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH (2004) Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 26:534-540
40. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779
41. Johansson I, Lindqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra-rapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829
42. Kirchheiner J, Brockmoller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphism. Clin Pharmacol Ther 77:1-16
43. Krajinovic M, Maghrabi A (2004) Pharmacogenetics of methotrexate. Pharmacogenomics 5:819-834
44. Kreutz R, Zurcher H, Kain S, Martus P, Offerman G, Beige J (2004) The effect of variable CYP3A expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14:665-671
45. Krynetski E, Evans WE (2003) Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22:7403-7413
46. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Storm S, Thummel K, Boguski MS, Shuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
47. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A mediated metabolism. Adv Drug Deliv Rev 54:1271-1294
48. Lavedan C, Birznieks G, Dressman M, McCullough K, Paczkowski R, Torres R, Wolfgang C, Polymeropoulos M (2004) Translating the genome into individualized therapeutics. Drug Dev Res 62:371-382
49. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients. JAMA 297:1200-1205
50. Lee CR (2004) CYP2C9 genotype as a predictor of drug deposition in humans. Methods Find Exp Clin Pharmacol 26:463-472
51. Lee CG, Chong SS, Lee EJD (2004) Pharmacogenetics of the human MDR1 multidrug transporter. Curr Pharmacogenomics 2:1-11
52. Lesko LJ, Woodcock J (2004) Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 3:763-769
53. Llerena A, Dorado P, O'Kirwan F, Jepson R, Licinio J, Wong ML (2004) Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J 4:403-406
54. Lorenzi C, Tubazio V, Serretti A, De Ronchi D (2004) The use of DNA microarray in the pharmacogenetics of antidepressants: guidelines for a targeted approach. Curr Genomics 5:499-508
55. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30-34
56. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, Budde K, Roots I (2004) MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 58:548-553
57. Marsh S, Xiao M, Yu JS, Ahluwalia R, Minton M, Freimuth RR, Kwok P-Y, McLeod H L (2004) Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84:661-668
58. Martin AM, Nolan D, Gaudier S, Phillips E, Mallal S (2004) Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics 5:643-655
59. McLeod H, Siva C (2002) The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3:89-98
60. Meyer UA (2004) Pharmacogenetics: five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669-676
61. Muehlberger N, Schneeweiss S, Hasford J (1997) Adverse drug reaction monitoring cost and benefit consideration: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf 6:S71-S77
62. Nabel EG (2003) Cardiovascular disease. N Engl J Med 349:60-72
63. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, Priori SG (2000). Evidence for a cardiac ion channel mutation underlying drug induced QT prolongation and life-threatening arrhythmias. J Cardiovas Electrophysiol 11:691-696
64. Nebert DW, Vesell ES (2004) Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 500:267-280
65. Oscarson M (2003) Pharmacogenetics of drug metabolizing enzymes: importance for personalized medicine. Clin Chem Lab Med 41:573-580
66. Ostrovsky O, Nagler A, Korostishevsky M, Gazet E, Galski H (2004) Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various Jewish populations of Israel. Ther Drug Monitor 26:679-684
67. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genomic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388
68. Pelaia G, Vatrella A, Gallelli L, Cazzola M, Maselli R, Marsico SA (2004) Potential genetic influences on the response to asthma treatment. PuIm Pharmacol Ther 17:253-261
69. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT Jr, Rosendaal FR (2002) Diuretic therapy, the alpha adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 287:1680-1689
70. Rodi CP, Darnhofer-Patel B, Stanssens P, Zabeau M, van den Boom D (2002) A strategy for the rapid discovery of disease markers using the massarray system. Biotechniques 32:S62-S69
71. Root I, Gerloff T, Meisel C, Kirchheiner J, Goldammer M, Kaiser R, Laschinski G, Brockmoller J, Cascorbi I, Kleeberg U, Hildebrandt AG (2004) Pharmacogenetic-based new therapeutic concepts. Drug Metab Rev 36:617-638
72. Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5:645-656
73. Rosmond R (2004) Pharmacogenomic approaches in antidiabetic drug development. Drug Dev Res 62:207-212
74. Sakaeda T, Nakamura T, Okumura K (2004) Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem 4:1385-1398
75. Sankar P, Cho MK, Condit CM, Hunt LM, Koenig B, Marshall P, Soo-Jin Lee S, Spicer P (2004) Genetic research and health disparities. JAMA 291:2985-2989
76. Scharfetter J (2004) Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia: an update. Pharmacogenomics 5:691-698
77. Schoedel KA, Hoffman EB, Rao Y, Sellers EM, Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adults Caucasians. Pharmacogenetics 14:615-626
78. Shastry BS (2003) SNPs and haplotypes: genetic markers for disease and drug response. Int J Mol Med 11:379-382
79. Shastry BS (2004) Role of SNP/haplotype map in gene discovery and drug development. Drug Dev Res 62:143-150
80. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348:1442-1448
81. Smith NF, Figg WD, Sparreboom A (2004) Recent advances in pharmacogenetic approaches to anticancer drug development. Drug Dev Res 62:233-253
82. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393-10398
83. Thomas FJ, McLeod HL, Watters JW (2004) Pharmacogenomics: the influence of genomic variation on drug response. Curr Top Med Chem 4:236-240
84. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A (2004) CYP3A variation and the evolution of the salt-sensitivity variants. Am J Hum Genet 75:1059-1069
85. Van Aken J, Schmedders M, Feuerstein G, Kollek R (2003) Prospects and limits of pharmacogenetics: the thiopurine methyltransferase (TPMT) experience. Am J Pharmacogenomics 3:149-155
86. Van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939-950
87. Van Schaik RHN (2004) Implications of cytochrome P450 polymorphisms on the toxicity of antitumor agents. Ther Drug Monitor 26:236-240
88. Van de Vijver MJ, He Y D, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton M J, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
89. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL (2004) Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 101:11809-11814
90. Webster A, Martin P, Lewis G, Smart A (2004) Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 9:663-669
91. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529-537
92. Weinshilboum R, Wang L (2004) Pharmacogenomics: bench to bed side. Nat Rev Drug Discov 3:739-748
93. Wojnowski L (2004) Genetics of the variable expression of CYP3A in human. Ther Drug Monitor 26:192-199
94. Xie HG, Kim RB, Wood AJ, Stein CM (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41:815-850
95. Yee DL, Bray PF (2004) Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. Semin Thromb Hemost 30:591-600